ORGENESIS INC (ORGS)

7.98
0.27 3.27
OTC
Prev Close 8.25
Open 8.35
Day Low/High 7.61 / 8.35
52 Wk Low/High 2.76 / 11.76
Volume 14.28K
Exchange OTC
Shares Outstanding 9.87B
Market Cap 75.13M
Div & Yield N.A. (N.A)

Latest News

Orgenesis Announces A Strategic Corporate Regrouping Of Its CDMO Activities Under The Global MaSTherCell Brand & Service Offerings Alignment

Orgenesis Announces A Strategic Corporate Regrouping Of Its CDMO Activities Under The Global MaSTherCell Brand & Service Offerings Alignment

MaSTherCell and Global CDMO Partners will be Presenting the New Global Branding at the Phacilitate Cell & Gene Therapy Meeting in Miami

Orgenesis And Pall Corporation Partnership Accomplishes Project Financed By The BIRD Foundation

Orgenesis And Pall Corporation Partnership Accomplishes Project Financed By The BIRD Foundation

Orgenesis and Pall Corporation originally received BIRD Grant in 2015 to co-develop a viral transduction production process for the treatment of diabetes.

Orgenesis Subsidiary MaSTherCell Raises 5 Million Euro Equity Investment From SFPI-FPIM

Orgenesis Subsidiary MaSTherCell Raises 5 Million Euro Equity Investment From SFPI-FPIM

MaSTherCell, the leading cell therapy CDMO, will use the proceeds of this investment to accelerate the delivery of its state of the art commercial unit in Belgium and leverage its expertise within the Orgenesis global CDMO network

Orgenesis And ATMI Enter Into Process Development Agreement

Orgenesis And ATMI Enter Into Process Development Agreement

Orgenesis Novel Therapeutic Technology Enabled by ATMI Investment and Bioreactor Technology

Orgenesis To Present At ATTD 2013

Orgenesis To Present At ATTD 2013

Orgenesis Appoints Leading Diabetes Expert, Camillo Ricordi, M.D., To Scientific Advisory Board

Orgenesis Appoints Leading Diabetes Expert, Camillo Ricordi, M.D., To Scientific Advisory Board

Orgenesis Inc. (OTCBB:ORGS) (“Orgenesis” or the “Company”), a development-stage company with a novel therapeutic technology dedicated to converting a patient’s own liver cells into functioning ...

Orgenesis Meets With The Paul-Ehrlich Institute

Orgenesis Meets With The Paul-Ehrlich Institute

Orgenesis Inc. (OTCBB:ORGS) (“Orgenesis” or the “Company”), a development-stage company with a novel therapeutic technology dedicated to converting a patient’s own liver cells into functioning ...

Orgenesis Enters Into R&D Agreement With The Fraunhofer IGB

Orgenesis Enters Into R&D Agreement With The Fraunhofer IGB

Orgenesis Inc. (OTCBB:ORGS) (“Orgenesis” or the “Company”), a development-stage company with a novel therapeutic technology dedicated to converting a patient’s own liver cells into functioning ...

Orgenesis Presents Technology Update To FDA/CBER Experts

Orgenesis Presents Technology Update To FDA/CBER Experts

Orgenesis Inc. (OTCBB:ORGS) (“Orgenesis” or the “Company”), a development-stage company with a novel therapeutic technology dedicated to converting a patient’s own liver cells into functioning ...

Orgenesis To Sponsor And Present At ESGCT 20th Anniversary Congress

Orgenesis To Sponsor And Present At ESGCT 20th Anniversary Congress

Orgenesis Inc. (ORGS) (“Orgenesis” or the “Company”), a development-stage company with a novel therapeutic technology dedicated to converting a patient’s own liver cells into functioning ...

Orgenesis Spotlighted In August 2012 Issue Of Drug Discovery News

Orgenesis Spotlighted In August 2012 Issue Of Drug Discovery News

Orgenesis Inc. (OTCBB: ORGS) (“Orgenesis” or “the Company”), a development-stage company with a novel therapeutic technology dedicated to converting a patient’s own liver cells into functioning ...

Orgenesis Chief Science Officer Describes Science In Two Online Publications

Orgenesis Chief Science Officer Describes Science In Two Online Publications

Orgenesis Inc. (OTCBB: ORGS) (“Orgenesis” or “the Company”), a development-stage company with a novel therapeutic technology dedicated to converting a patient’s own liver cells into functioning ...

Orgenesis Inc. Announces Definitive Agreement To Acquire Autologous Insulin Producing Cells (AIPC) Regeneration Technology.

Orgenesis Inc. Announces Definitive Agreement To Acquire Autologous Insulin Producing Cells (AIPC) Regeneration Technology.

Orgenesis Inc., ( OTCBB: ORGS) (the “Company”) announced today that pursuant to a licensing agreement dated February 2, 2012 with Tel Hashomer - Medical Research, Infrastructure and Services Ltd.